|
Steatohepatitis
|
0.320 |
Biomarker
|
disease |
BEFREE |
Here, we found decreased CYP3A4 and increased miR-200a-3p and miR-150-5p in LO2 cells with free fatty acid (FFA)-induced steatosis.
|
31191607 |
2019 |
|
Steatohepatitis
|
0.320 |
Biomarker
|
disease |
BEFREE |
The expression of miR-150 was up-regulated dramatically in both human NAFLD patients and HFD mice model, as well as in hepatocytes treated with oleic acid. miR-150 deficiency ameliorated the hepatic steatosis and insulin resistance significantly in NAFLD mice. miR-150 deficiency decreased the expression of genes related to fatty acid uptake, synthesis and gluconeogenesis, while increased the expression of genes related to fatty acid β-oxidation.
|
29107687 |
2017 |
|
Steatohepatitis
|
0.320 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Fatty Liver
|
0.310 |
Biomarker
|
disease |
BEFREE |
The expression of miR-150 was up-regulated dramatically in both human NAFLD patients and HFD mice model, as well as in hepatocytes treated with oleic acid. miR-150 deficiency ameliorated the hepatic steatosis and insulin resistance significantly in NAFLD mice. miR-150 deficiency decreased the expression of genes related to fatty acid uptake, synthesis and gluconeogenesis, while increased the expression of genes related to fatty acid β-oxidation.
|
29107687 |
2017 |
|
Fatty Liver
|
0.310 |
Biomarker
|
disease |
CTD_human |
Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis.
|
22363424 |
2012 |
|
Hepatitis, Toxic
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Liver Disease
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis, Drug-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Drug-Induced Acute Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemical and Drug Induced Liver Injury
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Chemically-Induced Liver Toxicity
|
0.300 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Pancreatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
|
27840954 |
2016 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, we reported a negative correlation between miR-150 and β-catenin in colorectal cancer.
|
31731194 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, it was implied that miR-150 could inhibit colorectal cancer progression and serve as a tumor suppressor via inactivating β-catenin pathway.
|
31731194 |
2020 |
|
Malignant neoplasm of colon and/or rectum
|
0.100 |
Biomarker
|
disease |
BEFREE |
Meanwhile, we reported a negative correlation between miR-150 and β-catenin in colorectal cancer.
|
31731194 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of lncRNA CASC11 mediated the inhibition of miRNA-150 expression in cancer cells, while miRNA-150 overexpression did not significantly alter lncRNA CASC11 expression. lncRNA CASC11 overexpression promoted, while miRNA-150 overexpression inhibited cancer cell proliferation. miRNA-150 also attenuated the enhancing effects of lncRNA CASC11 overexpression on cancer cell proliferation.
|
30916832 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Background:</b> One of our previous studies have demonstrated that the cancer suppressor miR-150 regulated the progression of colorectal cancer (CRC) by down-regulating v-myb avian myeloblastosis viral oncogene homolog (c-Myb).
|
31205515 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the abundance of the oncogenic miR-150-5p in blood of COPD patients was predictive for the development of cancer.
|
31569706 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vitro assays revealed that ectopic expression of <i>miR-150-5p</i> and <i>miR-150-3p</i> inhibited cancer cell malignancy.
|
31052206 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We have reported previously that, in myeloid and lymphoid malignancies associated with dysregulated fibroblast growth factor receptor 1 (FGFR1) activities, miR-150-5p is down-regulated compared with healthy cells.
|
31628193 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings demonstrate that circARHGAP10 suppresses NSCLC progression by acting as a miR-150-5p sponge to promote GLUT1 expression.
|
31561126 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-150-5p inhibition or HMGA2 overexpression counteracted the effects of ZFAS1 knockdown on NSCLC cell proliferative, invasive potentials and apoptotic rates.
|
31692094 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that miR-150-5p functions as a CSC suppressor and that overexpression of miR-150-5p may be a novel strategy to inhibit CSC-induced metastasis and recurrence in NSCLC.
|
31121479 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of EPG5 promoted NSCLC cell proliferation, and attenuated the effects of miR-150. c-myc gene was identified as a miR-150 transcriptional factor which increased miR-150 accumulation, therefore pharmacologically or genetically inhibiting c-myc/miR-150 expression significantly inhibited NSCLC cell growth <i>in vitro</i> and <i>in vivo</i>.
|
31410206 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-150 has been demonstrated to inhibit tumor progression in various human cancers, including colorectal cancer, ovarian cancer, and thyroid cancer.
|
29690954 |
2019 |